on AMOEBA (EPA:ALMIB)
Strategic advances for Amoéba before the launch of AXPERA
Amoéba, a specialist in microbiological solutions, made progress in biocontrol and cosmetics during the first half of 2025. The approval of its active substance by the European Commission and the distribution agreement with Koppert herald the commercialization of AXPERA in 2026. An agreement with Metron Technology targets the Chinese market for their cosmetic ingredient. Financially, Amoéba strengthened its structure with a €14 million capital increase in July 2025, adjusting its cash flow horizon. The commercial launch of AXPERA is in preparation for 2026, while the company explores biofertilizers to expand its profitability.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all AMOEBA news